Scarica l'app Stockscreener
41.41
1.40%
0.57
Precedente Chiudi:
$40.84
Aprire:
$40.87
Volume 24 ore:
1.44M
Relative Volume:
0.82
Capitalizzazione di mercato:
$6.60B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-13.62
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
-3.81%
1M Prestazione:
-0.77%
6M Prestazione:
+34.27%
1 anno Prestazione:
-12.01%
Intervallo 1D:
$40.37
$41.42
Intervallo di 1 settimana:
$40.03
$42.87
Portata 52W:
$23.95
$50.43
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
41.41 | 6.51B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Ionis Pharmaceuticals (IONS) Analyst Rating Update by UBS | IONS Stock News - GuruFocus
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Will Ionis Pharmaceuticals' (IONS) Return to Profitability and Raised Guidance Shift Its Investment Narrative? - simplywall.st
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Insider Transactions Reported | Ionis Pharmaceuticals(IONS)saw insider trading activity on 8/6/2025 - AInvest
Ionis Pharmaceuticals EVP Geary Richard S sells 10,000 shares at $42.86/share on August 5. - AInvest
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ionis Pharma EVP Schneider sells $408,701 in stock By Investing.com - Investing.com South Africa
Hereditary Transthyretin Amyloidosis (hATTR) Pipeline - openPR.com
Ionis Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Ionis Pharmaceuticals (IONS): Morgan Stanley Upgrade and Future ProspectsNews and Statistics - IndexBox
Ionis Pharmaceuticals Inc. Stock Lags Behind Sector BenchmarksHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
Why Morgan Stanley Upgraded This Biotech Stock to a Buy - Yahoo Finance
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency - MSN
What analysts say about Ionis Pharmaceuticals Inc. stockBreakout profit opportunities - Jammu Links News
How does Ionis Pharmaceuticals Inc. compare to its industry peersGet exclusive access to expert stock recommendations - Jammu Links News
What are Ionis Pharmaceuticals Inc. company’s key revenue driversFree Popular Stock Recommendations - Jammu Links News
What institutional investors are buying Ionis Pharmaceuticals Inc. stockCapitalize on market momentum for maximum gains - Jammu Links News
Ionis Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Is it the right time to buy Ionis Pharmaceuticals Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
Why is Ionis Pharmaceuticals Inc. stock attracting strong analyst attentionAchieve breakthrough profits with expert advice - Jammu Links News
Is Ionis Pharmaceuticals Inc. a growth stock or a value stockMarket-crushing profits - Jammu Links News
Ionis raises 2025 revenue guidance to $850M with Tryngolza momentum and Donidalorsen launch on track - MSN
How volatile is Ionis Pharmaceuticals Inc. stock compared to the marketCapital growth strategies that work - Jammu Links News
What makes Ionis Pharmaceuticals Inc. stock price move sharplyBuild wealth with high-performing stocks - Jammu Links News
What are analysts’ price targets for Ionis Pharmaceuticals Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
What is Ionis Pharmaceuticals Inc. company’s growth strategyUnprecedented profits - Jammu Links News
What catalysts could drive Ionis Pharmaceuticals Inc. stock higher in 2025Invest confidently with professional advice - Jammu Links News
When is Ionis Pharmaceuticals Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
Is Ionis Pharmaceuticals Inc. stock overvalued or undervaluedUnlock powerful market insights for success - Jammu Links News
Ionis Pharmaceuticals Inc. Stock Analysis and ForecastGet professional advice for portfolio optimization - Jammu Links News
What are the latest earnings results for Ionis Pharmaceuticals Inc.Maximize gains with data-driven trading alerts - Jammu Links News
Mixed Analyst Opinions on Healthcare Stocks: Teladoc, Ionis Pharmaceuticals, and Repligen - AInvest
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) - simplywall.st
How does Ionis Pharmaceuticals Inc. generate profit in a changing economyAI Powered Target Finder For Consistent Profits - Jammu Links News
Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Morgan Stanley Upgrades Ionis Pharmaceuticals (IONS) - MSN
Ionis (IONS) Q2 Revenue Soars 101% - The Globe and Mail
Raymond James Raises Ionis Pharmaceuticals (IONS) Price Target t - GuruFocus
UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach - insights.citeline.com
Ionis Pharmaceuticals: Raymond James raises PT to $64, maintains Strong Buy rating. - AInvest
Ionis Pharmaceuticals stock price target raised to $65 from $50 at H.C. Wainwright - Investing.com Canada
Ionis Pharmaceuticals: Q2 Earnings Snapshot - Huron Daily Tribune
Ionis reports second quarter 2025 financial results and highlights progress on key programs - BioSpace
Ionis Pharmaceuticals Inc (IONS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):